Stenocare bases itself on Danish pharmaceutical traditions
Driven by a desire to bring relief to chronic and terminally ill patients, Stenocare is building on true Danish pharmaceutical traditions to provide controlled substances to the world. Following a series of regulatory approvals of the company’s medicinal cannabis oils, Stenocare distinguishes itself in the growing market for medical cannabis and is now operating in the Danish, Swedish, Norwegian, German, British, and Australian markets. Here, the focus is on ensuring patients uniform and government-controlled cannabis oil products.
Stenocare is a Danish company that innovates, imports and sells prescription-based medical cannabis
Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain all three permits to cultivate, import, and handle medical cannabis oils for the Danish pilot scheme. At the same time, Stenocare is the first Danish company to have obtained approval for medical oil-based cannabis products for the Danish pilot scheme. Today, Stenocare operates in Denmark, Sweden, Norway, Germany, the United Kingdom, and Australia.
The pharmaceutical approach ensured crucial permits
Scientific controllability, transparent processes and uniformity of products are essential to the credibility of a pharmaceutical company and to gain the trust of physicians and the many possible patients on the market.
Stenocare strives to maintain full control over the ecosystem, risk management, and the optimisation of both processes and product quality. Although the cannabis plant is a natural product, it was essential to establish a development framework that ensures quality, control, and optimisation, allowing the products to be approved and accepted as prescription medications. Therefore, Stenocare collaborates with carefully selected suppliers who meet high standards for the production of these products,” says CEO Thomas Skovlund Schnegelsberg, emphasising that the technological and detailed cultivation process for cannabis plants takes place solely in climate-controlled indoor grow rooms.
Our high pharmaceutical standard has led to success in several markets, and the team behind Stenocare has succeeded in obtaining approvals in several important markets. Stenocare partners with leading producers of high-quality medical cannabis, and import their finished products to Denmark, Sweden, Norway, Germany, the United Kingdom, and Australia.
Focusing on innovation, Stenocare has developed products using an innovative and patented oil technology, ASTRUM, that paves the way for a new generation of medical cannabis.
Key results from our preclinical pharmacokinetic study in dogs, comparing ASTRUM oil with the commonly used MCT oil, show a significant improvement in blood absorption, more consistent absorption, and a faster time to maximum effect.
The new medical cannabis oil product ASTRUM 10:10 is now approved in Germany, Australia, and Norway and is strategically positioned to play a central role in Stenocare’s future growth strategy.
Stenocare’s core ambition is to provide more patients with a reliable, well-documented and easily accessible pharmaceutical alternative of the highest quality for the many patients who are seeking good clinical outcomes without being criminalised via illegal markets or losing their basic rights.
Stenocare founders want to improve the quality of life of patients and reduce the feeling of powerlessness of their loved ones
Like many other Danes, the founders of Stenocare themselves have witnessed family members losing sleep, appetite and peace of mind in the course of serious illnesses. This problem is a highly motivating factor for our management team every day, and for the three founders of Stenocare.
“Improving the quality of life for patients during the most challenging moments and giving them better days throughout their illness drives us at Stenocare and motivates us to strive for approvals to distribute and prescribe medical cannabis in an increasing number of markets. For the ill and their relatives, we do not want to ever have to go through such a powerless course of illness, as all three of us have witnessed such pain up close,” says CEO Thomas Skovlund Schnegelsberg.
Backed by a management team with broad competencies and with his many years of management and organisational experience, CEO Thomas Skovlund Schnegelsberg has entered a completely new industry with the goal of creating a more dignified course of illness and improving the quality of life for as many patients as possible through pharmaceutical-grade medical cannabis.
Stenocare’s goal is to become the leading European brand in prescription-based medical cannabis products which are manufactured according to pharmaceutical principles of Good Manufacturing Practice (GMP).
